Cardiac side effects of molecular targeted therapies: Towards a better dialogue between oncologists and cardiologists

Critical Reviews in Oncology/Hematology

Volumn 80, Issue 3, 2011, Pages 369-379

  Ederhy, Stephane ^a   Izzedine, Hassan ^b   Massard, Christophe ^c   Dufaitre, Ghislaine ^a   Spano, Jean Philippe ^b   Milano, Gerard ^d   Meuleman, Catherine ^a   Besse, Benjamin ^c   Boccara, Franck ^a   Kahyat, David ^b   Cohen, Ariel ^a   Soria, Jean Charles ^c  

^a HÔPITAL SAINT ANTOINE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d CENTRE ANTOINE LACASSAGNE   (France)

Author keywords

Cardiotoxicity; Heart failure; Hypertension; Molecular targeted agent

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; COMBRETASTATIN; DASATINIB; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCETAXEL; ENZASTAURIN; IMATINIB; L 778123; LAPATINIB; NILOTINIB; OMBRABULIN; PACLITAXEL; PLACEBO; PROTEIN KINASE C INHIBITOR; ROMIDEPSIN; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN INHIBITOR; VERAPAMIL;

ACUTE CORONARY SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTERY THROMBOSIS; BRADYCARDIA; BRAIN ISCHEMIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; CONGESTIVE HEART FAILURE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE ISCHEMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; MOLECULARLY TARGETED THERAPY; NONHUMAN; PATHOGENESIS; PR INTERVAL; QT PROLONGATION; REVIEW; SIDE EFFECT; SYSTOLIC DYSFUNCTION; TORSADE DES POINTES;

HEART DISEASES; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 80655127883     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2011.01.009     Document Type: Review

References (80)

1. Krause D.S., Van Etten RA Tyrosine kinases as targets for cancer therapy. N Engl J Med 2005, 353:172-187.
2. Ellis L.M., Hicklin DJ VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer 2008, 8:579-591.
3. Force T., Krause D.S., Van Etten RA Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007, 7:332-344.
4. Chu T.F., Rupnick M.A., Kerkela R., et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007, 370:2011-2019.
5. Kerkelä R., Grazette L., Yacobi R., et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006, 12:908-916.
6. Khakoo A.Y., Kassiotis C.M., Tannir N., et al. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 2008, 112:2500-2508.
7. Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008, 13:1084-1096.
8. Schmidinger M., Zielinski C.C., Vogl U.M., et al. Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 2008, 26:5204-5212.
9. Strevel E.L., Ing D.J., Siu LL Molecularly targeted oncology therapeutics and prolongation of the QT interval. J Clin Oncol 2007, 25:3362-3371.
10. Ederhy S., Cohen A., Dufaitre G., et al. QT interval prolongation among patients treated with angiogenesis inhibitors. Target Oncol 2009, 4:89-97.
11. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
12. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2000, 353:1673-1684.
13. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
14. Verheul H.M., Pinedo HM Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485.
15. Sane D.C., Anton L., Brosnihan KB Angiogenic growth factors and hypertension. Angiogenesis 2004, 7:193-201.
16. Veronese M.L., Mosenkis A., Flaherty K.T., et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006, 24:1363-1369.
17. Tam C.S., Galanos J., Seymour J.F., et al. Reversible posterior leukoencephalopathy syndrome complicating cytotoxic chemotherapy for hematologic malignancies. Am J Hematol 2004, 77:72-76.
18. Ozcan C., Wong S.J., Hari P Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-982.
19. Glusker P., Recht L., Lane B Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006, 354:980-982.
20. Govindarajan R., Adusumilli J., Baxter D.L., et al. Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006. J Clin Oncol 2006, 24:e48.
21. Hariawala M.D., Horowitz J.R., Esakof D., et al. VEGF improves myocardial blood flow but produces EDRF-mediated hypotension in porcine hearts. J Surg Res 1996, 63:77-82.
22. Li B., Ogasawara A.K., Yang R., et al. KDR (VEGF receptor 2) is the major mediator for the hypotensive effect of VEGF. Hypertension 2002, 39:1095-1100.
23. Eppler S.M., Combs D.L., Henry T.D., et al. A target-mediated model to describe the pharmacokinetics and hemodynamic effects of recombinant human vascular endothelial growth factor in humans. Clin Pharmacol Ther 2002, 72:20-32.
24. Ciuffetti G., Schillaci G., Innocente S., et al. Capillary rarefaction and abnormal cardiovascular reactivity in hypertension. J Hypertens 2003, 21:2297-2303.
25. Mourad J.J., des Guetz G., Debbabi H., et al. Blood pressure rise following angiogenesis inhibition by bevacizumab. a crucial role for microcirculation. Ann Oncol 2008, 19:927-934.
26. Jessup M., Abraham W.T., Casey D.E., et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009, 119:1977-2016.
27. Izzedine H., Ederhy S., Goldwasser F., et al. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol 2009, 20:807-815.
28. Mancia G., Grassi G. European society of hypertension European society of cardiology: joint national committee VII and European society of hypertension/European society of cardiology guidelines for evaluating and treating hypertension. J Am Soc Nephrol 2005, 16:S74-S77.
29. Fonseca C., Oliveira A.G., Mota T., et al. Evaluation of the performance and concordance of clinical questionnaires for the diagnosis of heart failure in primary care. Eur J Heart Fail 2004, 6:813-820.
30. Fonseca C., Mota T., Morais H., et al. The diagnosis of heart failure in primary care: value of symptoms and signs. Eur J Heart Fail 2004, 6:795-800.
31. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006, 11:95-107.
32. Thomas J.T., Kelly R.F., Thomas S.J., et al. Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 2002, 112:437-445.
33. Fromme E.K., Eilers K.M., Mori M., et al. How accurate is clinician reporting of chemotherapy adverse effects? a comparison with patient-reported symptoms from the Quality-of-Life Questionnaire C30. J Clin Oncol 2004, 22:3485-3490.
34. Maisel A.S., Krishnaswamy P., Nowak R.M., et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002, 347:161-167.
35. Burjonroppa S.C., Tong A.T., Xiao L.C., et al. Cancer patients with markedly elevated B-type natriuretic peptide may not have volume overload. Am J Clin Oncol 2007, 30:287-293.
36. Popat S., Smith I.E. Therapy insight: anthracyclines and trastuzumab - the optimal management of cardiotoxic side effects. Nat Clin Pract Oncol 2008, 5:324-335.
37. Viani G.A., Afonso S.L., Stefano E.J., et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007, 7:153-157.
38. Atallah E., Durand J.B., Kantarjian H., et al. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007, 110:1233-1237.
39. Verweij J., Casali P.G., Kotasek D., et al. Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005. Eur J Cancer 2007, 43:974-978.
40. Paul M.K., Mukhopadhyay A.K. Tyrosine kinase - role and significance in Cancer. Int J Med Sci 2004, 1:101-115.
41. Boyce M., Bryant K.F., Jousse C., et al. A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress. Science 2005, 307:935-939.
42. Pattacini L., Mancini M., Mazzacurati L., et al. Endoplasmic reticulum stress initiates apoptotic death induced by STI571 inhibition of p210 bcr-abl tyrosine kinase. Leuk Res 2004, 28:191-202.
43. Hantschel O., Rix U., Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma 2008, 49:615-619.
44. Quintás-Cardama A., Kantarjian H., Cortes J. Flying under the radar: the new wave of BCR-ABL inhibitors. Nat Rev Drug Discov 2007, 6:834-848.
45. Fernández A., Sanguino A., Peng Z., et al. An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic. J Clin Invest 2007, 117:4044-4054.
46. Perez E.A., Koehler M., Byrne J., et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008, 83:679-686.
47. Guarneri V., Lenihan D.J., Valero V., et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D Anderson Cancer Center experience. J Clin Oncol 2006, 24:4107-4115.
48. Ewer M.S., Vooletich M.T., Durand J.B., et al. Reversibility of trastuzumab related cardiotoxicity: new insights based on clinical course and response to medical treatment. J Clin Oncol 2005, 23:7820-7826.
49. Demetri G.D., van Oosterom A.T., Garrett C.R., et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
50. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
51. Telli M.L., Witteles R.M., Fisher G.A., et al. Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 2008, 19:1613-1628.
52. Jones A.L., Barlow M., Barrett-Lee P.J., et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. Br J Cancer 2009, 100:684-692.
53. Haverkamp W., Breithardt G., Camm A.J., et al. The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000, 47:219-233.
54. Sandor V., Bakke S., Robey R.W., et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res 2002, 8:718-728.
55. Piekarz R.L., Frye A.R., Wright J.J., et al. Cardiac studies in patients treated with depsipeptide FK229, in a phase II trial for T-cell lymphoma. Clin Cancer Res 2006, 12:3762-3772.
56. Highlights of Prescribing Information: Sutent® (sunitinib malate) capsules, oral: Initial U.S Approval 2006. http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021938s006s007s008lbl.pdf.
57. Herbst R.S., Heymach J.V., O'Reilly M.S., et al. Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. Expert Opin Investig Drugs 2007, 16:239-249.
58. Holden S.N., Eckhardt S.G., Basser R., et al. Clinical evaluation of ZD6474, an orally active inhibitor of VEGF and EGF receptor signaling, in patients with solid, malignant tumors. Ann Oncol 2005, 16:1391-1397.
59. Miller K.D., Trigo J.M., Wheeler C., et al. Multicenter phase II trial of ZD6474, a vascular endothelial growth factor receptor-2 and epidermal growth factor receptor tyrosine kinase inhibitor, in patients with previously treated metastastic breast cancer. Clin Cancer Res 2005, 11:3369-3376.
60. Heymach J.V., Johnson B.E., Prager D., et al. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 2007, 25:4270-4277.
61. Kiura K., Nakagawa K., Shinkai T., et al. A randomized, double-blind, phase IIa dose-finding study of vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. J Thorac Oncol 2008, 3:386-393.
62. Kovacs M.J., Reece D.E., Marcellus D., et al. A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma - NCIC CTG IND.145. Invest New Drugs 2006, 24:529-535.
63. Kantarjian H., Giles F., Wunderle L., et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006, 354:2542-2551.
64. Hazarika M., Jiang X., Liu Q., et al. Tasigna for chronic and accelerated phase Philadelphia chromosome - positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res 2008, 14:5325-5331.
65. Kantarjian H.M., Giles F., Gattermann N., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood 2007, 110:3540-3546.
66. le Coutre P., Ottmann O.G., Giles F., et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008, 111:1834-1839.
67. US Food and Drug Administration (FDA): Dasatinib (BMS-35825) Oncologic Drug Advisory Comitee Briefing Document NDA 21-96 2006, FDA, p. 52.
68. Dowlati A., Robertson K., Cooney M., et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin A-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res 2002, 62:3408-3416.
69. Britten C.D., Rowinsky E.K., Soignet S., et al. A phase I and pharmacological study of the farnesyl protein transferase inhibitor L-778123 in patients with solid malignancies. Clin Cancer Res 2001, 7:3894-3903.
70. Sharma S., Britten C., Spriggs D. A phase I and PK study of farnesyl transferase inhibitor L-778, 123 administered as a seven day continuous infusion in combination with paclitaxel. Proc Am Soc Clin Oncol 2000, 19:185a.
71. Carducci M.A., Musib L., Kies M.S., et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. J Clin Oncol 2006, 24:4092-4099.
72. Rademaker-Lakhai J.M., Beerepoot L.V., Mehra N., et al. Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer. Clin Cancer Res 2007, 13:4474-4481.
73. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 15(99):1232-1239.
74. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
75. Cooney M.M., Radivoyevitch T., Dowlati A., et al. Cardiovascular safety profile of combretastatin A4 phosphate in a single-dose phase I study in patients with advanced cancer. Clin Cancer Res 2004, 10:96-100.
76. Tolcher A.W., Forero L., Celio P. Phase I, pharmacokinetic, and DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days. Proc Am Soc Clin Oncol 2003, 22.
77. Sessa C., LoRusso P., Tolcher A.W. A Pharmacokinetic and DCE-MRI-dynamic Phase I study of the antivascular combretastatin analogue AVE8062A administered every 3 weeks. Proc Am Assoc Cancer Res 2005, 46. (abstr 5827).
78. Hanrahan E.O., Gonzalez-Angulo A.M., Giordano S.H., et al. Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. J Clin Oncol 2007, 25:4952-4960.
79. Fleissig A., Jenkins V., Catt S., et al. Multidisciplinary teams in cancer care: are they effective in the UK?. Lancet Oncol 2006, 7:935-943.
80. Forrest L.M., McMillan D.C., McArdle C.S., et al. An evaluation of the impact of a multidisciplinary team, in a single centre, on treatment and survival in patients with inoperable non-small-cell lung cancer. Br J Cancer 2005, 93:977-978.